drugset / Trial / NCT00852202

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

NCT00852202

Phase 2 Completed 234 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression.

Timeline

Start
2009-06-30
Primary completion
2010-06-15
Completion
2010-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 0.25 mg Oral
Subject Cariprazine Small molecule 0.75 mg Oral
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 3 mg Oral

Indications